Re: Cost-Effectiveness Analysis of Sacral Neuromodulation and Botulinum Toxin A Treatment for Patients With Idiopathic Overactive Bladder Editorial Comment

被引：0
|
作者：
Penson, David F.
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 06期
关键词：
D O I：
10.1016/j.juro.2012.02.2534
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2157 / 2158
页数：3
相关论文
共 50 条
  • [31] A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder
    Al-Azzawi, Issam S.
    Al-Hindawi, Haider T.
    ARAB JOURNAL OF UROLOGY, 2020, 18 (02) : 88 - 93
  • [32] Sacral Neuromodulation for the Treatment of Fecal Incontinence: Analysis of Cost-Effectiveness
    Indinnimeo, M.
    Ratto, C.
    Moschella, C. M.
    Fiore, A.
    Brosa, M.
    Giardina, S.
    DISEASES OF THE COLON & RECTUM, 2010, 53 (12) : 1661 - 1669
  • [33] The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial
    Amundsen, Cindy L.
    Richter, Holly E.
    Menefee, Shawn
    Vasavada, Sandip
    Rahn, David D.
    Kenton, Kim
    Harvie, Heidi S.
    Wallace, Dennis
    Meikle, Susie
    CONTEMPORARY CLINICAL TRIALS, 2014, 37 (02) : 272 - 283
  • [34] The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA Trial
    Hall, Evelyn
    OBSTETRICS AND GYNECOLOGY, 2017, 129 (01): : 201 - 201
  • [35] Re: Detailed Analysis of Adverse Events and Surgical Interventions in a Large Prospective Trial of Sacral Neuromodulation Therapy for Overactive Bladder Patients Editorial Comment
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2018, 199 (04): : 898 - 898
  • [36] Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2016, 195 (03): : 689 - 689
  • [37] COST UTILITY ANALYSIS OF SACRAL NEUROMODULATION VERSUS BOTOX A IN THE TREATMENT OF OVERACTIVE BLADDER IN COLOMBIA
    Castano, J. C.
    Lopera, A.
    Orozco, J. J.
    Valencia, J. E.
    VALUE IN HEALTH, 2014, 17 (03) : A294 - A294
  • [38] The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple, Christopher
    De Ridder, Dirk
    BJU INTERNATIONAL, 2009, 104 (09) : 1188 - 1190
  • [39] Re: Long-Term Outcome of the Use of Intravesical Botulinum Toxin for the Treatment of Overactive Bladder (OAB) Editorial Comment
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2013, 190 (05): : 1815 - 1815
  • [40] A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN
    Arlandis, S.
    Castro, D.
    Errando, C.
    Fernandez, E.
    Jimenez, M.
    Gonzalez, P.
    Crespo, C.
    Stauble, F.
    Rodriguez, J. M.
    GACETA SANITARIA, 2009, 23 : 200 - 201
12345